Abstract
Pancreas Transplantation (PT) has become a therapeutic alternative to promote normoglycemia in Diabetes Mellitus type 1 (DM1) high-risk patients while protecting against secondary complications, but with the risk of adverse outcomes. Historically, the fear of early graft loss leads the selection to be extremely conservative in choosing organs for transplantation. Yet the number of organs …